Gyre Therapeutics (GYRE) Revenue (2016 - 2025)
Historic Revenue for Gyre Therapeutics (GYRE) over the last 16 years, with Q3 2025 value amounting to $30.6 million.
- Gyre Therapeutics' Revenue rose 1991.53% to $30.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $107.3 million, marking a year-over-year increase of 212.5%. This contributed to the annual value of $105.8 million for FY2024, which is 678.1% down from last year.
- Per Gyre Therapeutics' latest filing, its Revenue stood at $30.6 million for Q3 2025, which was up 1991.53% from $26.8 million recorded in Q2 2025.
- In the past 5 years, Gyre Therapeutics' Revenue ranged from a high of $101.5 million in Q4 2022 and a low of $794000.0 during Q1 2022
- Its 5-year average for Revenue is $24.0 million, with a median of $25.5 million in 2024.
- As far as peak fluctuations go, Gyre Therapeutics' Revenue crashed by 9103.63% in 2021, and later surged by 405967.21% in 2022.
- Gyre Therapeutics' Revenue (Quarter) stood at $2.4 million in 2021, then skyrocketed by 4059.67% to $101.5 million in 2022, then plummeted by 73.25% to $27.1 million in 2023, then increased by 2.67% to $27.9 million in 2024, then grew by 9.66% to $30.6 million in 2025.
- Its last three reported values are $30.6 million in Q3 2025, $26.8 million for Q2 2025, and $22.1 million during Q1 2025.